Alderley Park

Gentronix Recognised With King’s Award After Record International Growth

Retrieved on:

Martedì, Maggio 7, 2024

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets.

Key Points:

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets.
View the full release here: https://www.businesswire.com/news/home/20240507716487/en/
Gentronix Recognised With King’s Award After Record International Growth (Photo: Business Wire)
Gentronix recorded total growth of 239% in overseas earnings over the past three years, with the percentage of total sales exported rising from 71% to 81% over the same period, driving revenue to in excess of £10m per annum.
The US has been a particularly strong area of growth and this market now makes up almost half of the firm’s international business, with demand continuing to increase across North America.
As a result of the business’s success and enhanced overseas trading, Gentronix has received a prestigious King’s Award for Enterprise for 2024, marking its success in the area of International Trade.

Redx and Jounce Announce Recommended Business Combination

Retrieved on:

Giovedì, Febbraio 23, 2023

ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis. Jounce is a clinical-stage immunotherapy company, dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker approach. The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points in the near and medium term.

Key Points:

RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce
Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025
ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.
The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points in the near and medium term.
Named Redx Inc., the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX.
Led by current Redx CEO Lisa Anson, Dr Jane Griffiths current Redx Chair will become the non-executive Chair of the combined group; with the Board including representatives from both Redx and Jounce, in line with the relative shareholding percentages.

Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

Retrieved on:

Venerdì, Marzo 19, 2021

Companies, Life sciences, Health sciences, AstraZeneca, Medical research, Södertälje Municipality, Alderley Park

The Alderley Park Oncology Development Program is funded by Innovate UK and Cancer Research UK and supported by major oncology-focused pharmaceutical companies including, AstraZeneca, J&J, GSK and Roche.

Key Points:

The Alderley Park Oncology Development Program is funded by Innovate UK and Cancer Research UK and supported by major oncology-focused pharmaceutical companies including, AstraZeneca, J&J, GSK and Roche.
Artelos application is focused on developing a pathway to a validated FABP5 biomarker.
We are honored that our application has been accepted into the Alderley Park Oncology Program, stated Gregory D. Gorgas, Artelos President and Chief Executive Officer.
Artelo Biosciences, Inc.is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system.

BDD Appoints Ex-AstraZeneca VP Joanne Kelley as Non-executive Director to the Board

Retrieved on:

Venerdì, Ottobre 12, 2018

BDD, Alderley Park, Economy of the United Kingdom

BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.

Key Points:

BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.
Jo is a Life Sciences Business Development professional and brings an outstanding track record of strategy development, deal preparation and execution to the BDD Board.
She now works as a Director of Alderley Park Ventures and is a non executive director at UMI3, the innovation company of Manchester University.
Commenting on her appointment, Jo said "I am delighted to be joining the Board of BDD at such an exciting time in the company's expansion.